Your browser doesn't support javascript.
loading
Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention.
Chehrevar, Morteza; Vafa, Reza Golchin; Rahmani, Mohammadhossein; Parizi, Mohammadjavad Mehdizadeh; Ahmadi, Amin; Zamiri, Bardia; Heydarzadeh, Reza; Montaseri, Mohammad; Hosseini, Seyed Ali; Kojuri, Javad.
Afiliación
  • Chehrevar M; Cardiology Department, Shiraz University of Medical Sciences Shiraz, Iran.
  • Vafa RG; Professor Kojuri Cardiology Clinic Shiraz, Iran.
  • Rahmani M; Professor Kojuri Cardiology Clinic Shiraz, Iran.
  • Parizi MM; Professor Kojuri Cardiology Clinic Shiraz, Iran.
  • Ahmadi A; Professor Kojuri Cardiology Clinic Shiraz, Iran.
  • Zamiri B; Professor Kojuri Cardiology Clinic Shiraz, Iran.
  • Heydarzadeh R; Professor Kojuri Cardiology Clinic Shiraz, Iran.
  • Montaseri M; Professor Kojuri Cardiology Clinic Shiraz, Iran.
  • Hosseini SA; Student Research Committee, Shiraz University of Medical Sciences Shiraz, Iran.
  • Kojuri J; Cardiology Department, Shiraz University of Medical Sciences Shiraz, Iran.
Interv Cardiol ; 17: e20, 2022 Jan.
Article en En | MEDLINE | ID: mdl-36890806
Background: Although statins decrease mortality in coronary artery disease, the effect of high-dose statins and duration of therapy post-percutaneous coronary intervention (PCI) is not well addressed. Aim: To determine the effective dose of statin to prevent major adverse cardiovascular events (MACEs), such as acute coronary syndrome, stroke, myocardial infarction, revascularisation and cardiac death, after PCI in patients with chronic coronary syndrome. Methods: In this randomised, double-blind clinical trial, all chronic coronary syndrome patients with a recent history of PCI were randomly divided into two groups after 1 month of high-dose rosuvastatin therapy. Over the next year, the first group received rosuvastatin 5 mg daily (moderate intensity), while the second received rosuvastatin 40 mg daily (high intensity). Participants were evaluated in terms of high-sensitivity C-reactive protein and MACEs. Results: The 582 eligible patients were divided into group 1 (n=295) and group 2 (n=287). There was no significant difference between the two groups in terms of sex, age, hypertension, diabetes, smoking, previous history of PCI or history of coronary artery bypass grafting (p>0.05). There were no statistically significant differences in MACE and high-sensitivity C-reactive protein after 1 year between the two groups (p=0.66). Conclusion: The high-dose group had lower LDL levels. However, given the lack of association between high-intensity statins and MACEs in the first year after PCI among chronic coronary syndrome patients, the use of moderate-intensity statins may be as effective as high-intensity statins, and treatment based on LDL targets may suffice.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Interv Cardiol Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Interv Cardiol Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido